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Background and aims: Iron deficiency is common in inflammatory bowel disease, yet oral 
iron therapy may worsen the disease symptoms and increase systemic and local oxidative stress. 
The aim of this study was to compare the effects of oral ferrous sulfate and iron polymaltose 
complex on inflammatory and oxidative stress markers in colitic rats.
Methods: Animals were divided into four groups with ten animals each. Rats of three groups 
received dextran sodium sulfate to induce colitis and animals of two of these groups received 
5 mg iron/kg of body weight a day, as ferrous sulfate or iron polymaltose complex, for 7 days. 
Gross colon anatomy, histology of colon and liver, stainings of L-ferritin, Prussian blue, hepcidin, 
tumor necrosis factor-α, and interleukin-6, as well serum levels of liver enzymes, inflammatory 
markers, and iron markers, were assessed.
Results: Body weight, gross anatomy, crypt injury and inflammation scores, inflammatory 
parameters in liver and colon, as well as serum and liver hepcidin levels were not significantly 
different between colitic animals without iron treatment and colitic animals treated with iron 
polymaltose complex. In contrast, ferrous sulfate treatment caused significant worsening of these 
parameters. As opposed to ferrous sulfate, iron polymaltose complex caused less or no additional 
oxidative stress in the colon and liver compared to colitic animals without iron treatment.
Conclusion: Iron polymaltose complex had negligible effects on colonic tissue erosion, local 
or systemic oxidative stress, and local or systemic inflammation, even at high therapeutic 
doses, and may thus represent a valuable oral treatment of iron deficiency in inflammatory 
bowel disease.
Keywords: preclinical, oral iron treatment, tolerability, colonic tissue erosion, inflammatory 
bowel disease
Introduction
Patients with inflammatory bowel disease (IBD) commonly develop iron deficiency 
and, if left untreated, they can develop iron deficiency anemia (IDA). In IBD, IDA is 
caused mainly by blood loss and/or impaired iron absorption from the gut,1 as well as 
by reduced iron availability for erythropoiesis.2 Under inflammatory conditions, iron 
sequestration is induced by an increased expression of hepcidin, which binds to and 
leads to degradation of the iron-export protein ferroportin and thus inhibits the release 
of iron from the enterocytes and from the macrophages of the reticuloendothelial 
system. As a consequence, the absorption and availability of iron is decreased.3 Oral 
iron, usually in the form of ferrous sulfate (FS) or ferrous fumarate (FF), is recom-
mended as firstline therapy for IDA in IBD in some guidelines,4 although intravenous 
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iron therapy is recommended as a preferred treatment 
option in other guidelines5 and in a number of recent 
publications.6–8
It has been extensively reported that overdoses of fer-
rous salts lead to systemic toxic effects9,10 as well as direct 
corrosive effects, which can result in mucosal necrosis and 
ulceration.11,12 However, therapeutic doses of ferrous salts 
have been shown to cause severe gastric and esophageal 
injury.13–15 In IBD patients, FS has been shown to worsen 
the inflammatory state in the colon16 and has been suggested 
to trigger ulcerative colitis.17 Similarly, FF has been shown 
to worsen the symptoms in patients affected by Crohn’s 
disease.18,19 Upon administration of a standard therapeutic 
dose of FS (60–100 mg Fe), rapid, uncontrolled absorption of 
iron causes high levels of serum iron and transferrin saturation 
(TSAT) and, thus, may lead to significant amounts of non–
transferrin-bound iron (NTBI).20–23 In particular in chronic 
iron-overload disorders, NTBI has been shown to cause organ 
toxicity, as it is taken up unselectively by highly vascular 
tissues such as liver, heart, and endocrine system, where it 
may increase the intracellular labile iron pool and induce 
oxidative stress.24,25 Increased levels of oxidative stress mark-
ers (eg, thiobarbituric-acid-reactive substances [TBARS] 
and 8-hydroxy-2-deoxyguanosine) have been reported 
after therapeutic doses of FS combined with vitamin C 
in healthy volunteers.26,27 Similarly, increased markers 
of lipid peroxidation were observed in patients with iron 
deficiency after FS treatment.28,29 Thus, FS may exacerbate 
the oxidative stress that usually occurs under inflammatory 
conditions. Yet, IDA itself has also been shown to cause 
oxidative stress, due to (among other aspects) a shortage in 
iron-based antioxidant enzymes.25
Iron polymaltose complex (IPC) is a complex of a 
polynuclear iron(III)-oxyhydroxide core with polymaltose 
ligands that liberates ferric ions in a controlled way and 
thus assures a very low toxicity and good tolerability.30 
For IPC, no cases of acute poisoning have been reported 
even when given accidentally at very high doses,30,31 and 
no cases of local injury of the mucosa have been linked to 
IPC treatment. Because iron from IPC is taken up through 
the enterocytes in a controlled manner, administration of a 
therapeutic dose of IPC does not lead to a fast increase in 
serum iron and TSAT levels and, thus, essentially no NTBI 
is observed.20,22,23 Gastrointestinal irritations may occur, but 
consistently lower rates are observed with IPC than with FS 
treatment.32 For instance, a clinical study in IBD patients 
comparing FS and IPC treatments over a course of 14 days 
showed an increase in lipid peroxidation markers with FS 
but not with IPC.33 Given that IDA in IBD patients tends 
to recur,34,35 and patients often undergo repeated regimens 
of iron therapy, possible long-term effects of the treatment 
should be considered. Thus, based on its better tolerability, 
IPC may represent a suitable treatment option.
Nonclinical studies in healthy rodents provided further 
insights into the toxicity, histological effects, quantitative 
results on local reactions, and oxidative stress caused by 
FS and IPC treatments.36,37 Moreover, the understanding of 
underlying principles in human IBD progressed with the use 
of rodent models with dextran sulfate sodium (DSS)-induced 
colitis.38,39 Previous studies investigated the effects of FF 
and iron pentacarbonyl treatments in rats with DSS-induced 
colitis,40,41 but, up until now, no direct comparison between 
FS and IPC was available in such a model. In the present 
study, we assessed the effects of iron therapy with FS and IPC 
in rats with DSS-induced colitis and compared their status 
with that of healthy animals as well as that of animals with 
colitis but without iron treatment. In particular, we assessed 
the potential of FS and IPC to further exacerbate the inflam-
mation and to increase the oxidative stress markers in rats 
with DSS-induced colitis.
Materials and methods
animals and treatments
All animal experiments were approved by the Hospital 
Aléman Ethics Committee and the Teaching and Research 
Committee, and were conducted according to the US National 
Institutes of Health Guide for the Care and Use of Laboratory 
Animals.42 All experiments were conducted with Sprague 
Dawley rats, aged 6 weeks old and weighing 200–250 g, at 
the Laboratory of Experimental Medicine, Hospital Aléman, 
Buenos Aires, Argentina. The rats were housed in a 
temperature-controlled room at 22°C±2°C and were fed 
standard rat chow (Cooperación, Buenos Aires, Argentina; 
iron content: 65 parts per million) ad libitum throughout the 
study. Forty rats were acclimatized for 7 days at the research 
laboratory and randomized into four groups (n=10) with equal 
proportions of male:female animals in each. Acute colitis was 
induced in all animals in groups 1–3 by addition of 30 g/L DSS 
(D6924; Sigma-Aldrich Co., St Louis, MO, USA; average 
molecular weight 9,000–20,000 Da) to the drinking water for 
7 days. Group 4 had free access to tap water (control group). 
In parallel, groups 2 and 3 were administered 5 mg iron/kg 
of body weight as FS (ferrous sulfate heptahydrate ALT No 
44982, batch BCBC3657, DSS + FS; Sigma-Aldrich Co.) 
or IPC (Maltofer® lot 92110011, DSS + IPC; Vifor Pharma, 
Zurich, Switzerland), respectively, by gavage for 7 days. 
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A dose of 5 mg iron/kg of body weight corresponds to 300 mg 
iron for a 60 kg human adult, ie, this dosage is in the upper range 
of a recommended dose for oral iron therapy (100−300 mg 
iron per day). Group 4 received saline (control group) and 
group 1 did not receive any treatment in addition to DSS 
(DSS, acute colitis reference group). On day 8, blood samples 
were collected after a 14 hour fast, and the animals were sac-
rificed. Liver and bowel were perfused with ice cold saline 
solution and removed for further analysis.
hematology and blood chemistry
Hemoglobin (Hb) levels were determined by Sysmex 
XT-1800i (Roche Diagnostic GmbH, Mannheim, Germany). 
Serum iron and the liver enzymes (aspartate aminotrans-
ferase [AST], alanine aminotransferase [ALT], and alkaline 
phosphatase [ALP]) were assessed by colorimetric and 
ultraviolet methods, respectively, with an Auto-analyzer 
Modular P800 with the corresponding reagents (Roche 
Diagnostic GmbH). Total iron binding capacity (TIBC) was 
determined with a colorimetric assay (Randox Laboratories 
Limited, Crumlin, Northern Ireland, UK). TSAT was cal-
culated as follows: TSAT (%) = [serum iron concentration 
(µg/L)/TIBC (µg/L)] ×100. Serum hepcidin was assessed by a 
commercially available enzyme-linked immunosorbent assay 
kit for hepcidin (Catalog No E91979; Uscn Life Science Inc., 
Wuhan, People’s Republic of China).
gross anatomy of the colon
The lesion index of the colon was determined according 
to the following scoring: 0= absence of lesion; 1= super-
ficial, one to five hemorrhagic points; 2= superficial, six 
to ten hemorrhagic points; 3= submucosal hemorrhagic 
lesions with small erosions; and 4= severe hemorrhagic 
lesions and some invasive lesions. A measure of the extent 
of involvement in each score was expressed as follows: 
grade 1=1%–25% of the surface area examined; grade 
2=26%–50%; grade 3=51%–75%; and grade 4=76%–100% 
of the surface area examined. The final score (cumulative 
score) was calculated as the product of the lesion index by 
the extent of involvement.
light microscopy
Portions of colon and liver were fixed in phosphate-buffered 
10% formaldehyde (pH 7.2) and embedded in paraffin. 
Three-micron sections were stained with hematoxylin–eosin. 
Prussian blue staining of the liver was performed according 
to Perls’ description,43,44 and were expressed as the percent-
age of positive immunostaining per area. All observations 
were performed with a Nikon E400 light microscope (Nikon 
Instruments, Melville, NY, USA).
Morphometric analysis
Histological sections from each animal were studied using 
an Image-Pro Plus version 4 image analyzer for Windows 
(Media Cybernetics, Inc., Rockville, MD, USA). Mor-
phological analyses were performed at a magnification of 
×100 or ×400 depending on the tissue evaluated, and the 
data were averaged. Crypt and inflammatory scores of 
the colon were determined by a pathologist blinded to the 
experimental group. The crypt injury was scored according 
to a validated scoring system:45 grade 0= intact crypt; grade 
1= loss of bottom third of the crypt; grade 2= loss of bottom 
two-thirds of the crypt; grade 3= loss of entire crypt with the 
surface epithelium remaining intact; and grade 4= loss of the 
entire crypt and surface epithelium (erosion). The severity 
of the inflammation of the colon was scored according to 
reference:46 grade 0= normal; grade 1= focal inflammatory 
cell infiltration, including polymorphonuclear leukocytes; 
grade 2= inflammatory cells infiltration, gland dropout; and 
grade 3= crypt abscess. As for assessment of the gross anat-
omy of the colon, a measure of the extent of involvement of 
the examined surface area in each score was expressed as fol-
lows: grade 1=1%–25% of the surface area examined; grade 
2=26%–50%; grade 3=51%–75%; and grade 4=76%–100% 
of the surface area examined. The final score is the product 
of either the inflammation or injury grade and the extent of 
involvement, ie, the inflammation cumulative score and the 
crypt injury cumulative score.
immunohistochemical analysis
Tissue ferritin was determined with antiferritin light-chain 
goat polyclonal immunoglobulin G antibody (sc-14420; 
Santa Cruz Biotechnology Inc., Dallas, TX, USA) at 1:100 
dilution, tissue hepcidin in liver and colon was determined 
with a rabbit polyclonal anti–hepcidin-25 antibody (ab30760; 
Abcam, Cambridge, MA, USA) at 1:100 dilution, tumor 
necrosis factor-α (TNF-α) was determined with a rat TNF-α 
antibody (AF-510-NA; R&D Systems, Inc., Minneapolis, 
MN, USA) at 1:50 dilution, and interleukin-6 (IL-6) was 
determined with an anti–IL-6 antibody (sc1265; Santa 
Cruz Biotechnology Inc.) at 1:100 dilution. Detection was 
carried out by a modified avidin–biotin–peroxidase com-
plex technique (VECTASTAIN Universal Elite ABC kit; 
Vector Laboratories, Ltd., Peterborough, UK) as described 
previously.47 The ferritin immunostainings of the colon 
were evaluated by a semiquantitative score according to the 
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following schedule: 0= absence of staining; 1= mild positive 
staining per villus; 2= moderate positive staining per villus; 
3= intense positive staining per villus; and 4= very intense 
positive staining per villus. Ferritin immunostainings of the 
liver and hepcidin, IL-6, and TNF-α immunostainings of 
liver and colon were expressed as the percentage of positive 
immunostaining per area.
Western blotting and densitometric 
analysis
Tissue samples from colon and liver were solubilized in 
1% triton detergent and analyzed by Western blotting as 
described previously.48 For assessing nitrosative stress, poly-
vinyl difluoride membranes with transferred proteins were 
probed with antinitrotyrosine antibody at 1:2,000 dilution 
(AB5411; EMD Millipore, Billerica, MA, USA). Inflam-
matory response was evaluated by probing for anti–TNF-α 
(AF-510-NA; R&D Systems, Inc.) at 1:1,000 dilution and 
IL-6 with an anti–IL-6 antibody (sc1265, Santa Cruz Biotech-
nology Inc.) at 1:1,000 dilution. Tissue hepcidin was probed 
with a rabbit polyclonal anti–hepcidin-25 antibody (ab30760; 
Abcam) at 1:1,000 dilution. After washing, membranes 
were probed with a horseradish peroxidase-conjugated goat 
antirabbit secondary antibody at dilution 1:20,000 (sc-2004; 
Santa Cruz Biotechnology Inc.). Specific bands were detected 
by enhanced chemiluminescence (ECL; Amersham Biosci-
ences Corp., Piscataway, NJ, USA). Autoradiographs were 
scanned and band intensities were quantified by digital densi-
tometry using Gel-Pro Analyzer 4.0 software (Media Cyber-
netics, Inc.). The data were recorded as mean optical density 
intensity. Equal protein loading of samples was confirmed by 
stripping polyvinyl difluoride membranes with a commer-
cial re-blot solution (Chemicon International Inc., Billerica, 
MA, USA) and then re-probing with anti–β-actin primary 
antibody (A5316; Sigma-Aldrich Co.) at 1:5,000 dilution; 
and horseradish peroxidase-conjugated goat antimouse sec-
ondary antibody (sc-2005; Santa Cruz Biotechnology Inc.) 
at 1:20,000 dilution followed by chemiluminescent detection 
and densitometric quantification as described earlier.
Oxidative stress parameter evaluation 
in colon mucosa and liver
A fraction of the whole liver and colon mucosa were 
homogenized (1:3, w/v) in ice-cold 0.25 mol/L sucrose solu-
tion. Reduced glutathione (GSH) and glutathione disulfide 
(GSSG) levels were determined in the 10,000× g supernatant 
following methods as previously described.49–51 TBARS and 
the activity of catalase, copper–zinc superoxide dismutase 
(CuZn-SOD), and glutathione peroxidase (GPx) were 
measured as described earlier52 in different homogenates or 
their supernatants.
statistical methods
Values were expressed as mean ± standard deviation. All 
statistical analyses were performed using absolute values 
and were processed through GraphPad Prism, version 5.01 
for Windows (GraphPad Software, Inc., La Jolla, CA, 
USA). Normality of the samples was determined by the 
Kolmogorov–Smirnov test. For parameters with a Gauss-
ian distribution, the groups were compared by analysis of 
variance (ANOVA); for parameters such as histological 
data with non-Gaussian distribution, comparisons were 
performed by the Kruskal–Wallis test (nonparametric 
ANOVA) and Dunn’s multiple comparison test. A poten-
tial relationship between serum or tissue hepcidin with 
the TNF-α and IL-6 values was assessed by Spearman 
nonparametric correlation. A value of P,0.05 was con-
sidered significant.
Results
All animals that received DSS developed severe, acute colitis, 
which became obvious by the development of bloody diar-
rhea between day 5 and day 6. At the end of the experiment 
(day 8, presurgery), variable degrees of hemorrhagic proctitis 
were observed.
Body weight and food consumption
Body weight and food intake in the groups that received DSS 
decreased over the course of the experiment as expected and 
were lower than in the control group, which showed a net 
gain in body weight (Table 1). The animals in the DSS and 
DSS + IPC groups had comparable changes in body weight 
and food intake, whereas those in the DSS + FS group had 
a significantly lower food intake and lost more weight than 
the animals in the other groups. Water consumption was 
higher in the control group than in the DSS-receiving groups. 
The water consumption and thus the DSS intake did not 
differ significantly between the groups that received DSS 
(Table 1).
hematology parameters
Hemoglobin, as well as the markers of iron status, serum 
iron, and TSAT, were significantly higher in the control 
group than in all other groups. Both types of oral iron 
supplementation failed to maintain an adequate iron status 
in this model (Table 1). Rats treated with FS had signifi-
cantly lower Hb values than those treated with IPC, and 
TSAT showed a corresponding significant difference. 
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TIBC was maintained in the DSS + IPC and the DSS + FS 
groups at the same level as in the control group, whereas 
TIBC in the DSS group was significantly lower than in the 
other groups.
Pathology and immunohistochemistry 
findings in the colon
For all groups with acute colitis (DSS, DSS + IPC, DSS + FS), 
gross anatomy of the colon showed numerous areas with loss 
of mucosal folds and a variable degree of mucosal edema and 
congestion, along with submucosal hemorrhage and focal 
ulceration (Figure 1). The gross anatomy cumulative score 
of the colon indicated substantially more serious lesions 
in the DSS + FS group versus the DSS + IPC and DSS 
groups. The gross anatomy cumulative scores of the 
DSS + IPC and the DSS groups were not significantly dif-
ferent (significant differences between groups with P,0.05 
in the following order: control , DSS ≈ DSS + IPC , 
DSS + FS). The gross anatomy lesion index and the extent 
of involvement showed the same relative order but with 
a nonsignificant difference of the extent of involvement 
between the two iron-supplemented groups (data not shown). 
Taken together, these data indicate that FS induced more 
severe macroscopic effects (based on the severity of the 
reaction or lesion index), and to a nonsignificant degree 
also more-widespread lesions, as shown by the extent of 
involvement. The injury was mainly located in the distal 
colon with crypt distortion and inflammatory cell infiltration, 
as indicated by the arrows in Figure 1. On the microscopic 
scale, the crypt injury cumulative score (Figure 1) as well as 
the crypt injury and extent of involvement scores (data not 
shown) showed a similar trend, with the DSS and DSS + IPC 
groups being significantly more inflamed than the control 
group but less so than the DSS + FS group (significant dif-
ferences between groups with P,0.05: control , DSS ≈ 
DSS + IPC , DSS + FS). Also, the inflammation cumula-
tive score of the colon yielded similar significant differ-
ences between groups (with P,0.05: control , DSS ≈ 
DSS + IPC , DSS + FS) (Figure 1).
The expression of L-ferritin (as L-ferritin staining) in the 
colon villi was lowest in the DSS group, whereas it was not 
significantly different between the iron-receiving groups and 
the control group (significant differences between groups 
with P,0.05: control ≈ DSS + FS ≈ DSS + IPC; DSS , 
control ≈ DSS + FS) (Figure 2).
The comparative levels of oxidative stress parameters 
in the colon followed the same pattern, with increasing 
oxidative stress in the different groups in the order con-
trol , DSS # DSS + IPC , DSS + FS (significant dif-
ferences are given in Figure 3). Colon TBARS levels, a 
marker of lipid peroxidation, were significantly higher in 
the DSS versus the control group, and oral iron treatments 
caused an additional significant increase in TBARS level, 
with FS causing a significantly more pronounced increase 
than IPC (Figure 3). Similar relative behaviors were found 
for CuZn-SOD and GPx, although the difference between 
the DSS + IPC and DSS groups was not significant for GPx 
levels (Figure 3). GSH levels significantly decreased with 
increasing oxidative stress; this inverse behavior was further 
reflected in the GSH:GSSG ratio between groups in the order 
Table 1 Body weight change, food intake, water consumption, hematology parameters, liver enzymes, and serum hepcidin levels with 
standard deviations for each group at the end of the study (day 8)
Control  
group
DSS group DSS +  
IPC group
DSS + FS  
group
Significant differences (P,0.05)
Bodyweight change (g/week) 29.0±3.8 -16.5±2.4 -18.2±3.3 -28.8±5.5 control . Dss ≈ Dss + iPc . Dss + Fs
Food intake (g/week) 140.2±8.1 114.2±7.4 111.4±8.5 96.5±6.5 control . Dss ≈ Dss + iPc . Dss + Fs
Water consumption (ml/day) 31.1±2.0 25.9±3.9 28.7±4.3 27.9±3.4 control . Dss = Dss + iPc . Dss + Fs
hematology parameters
hb (g/dl) 14.4±0.5 10.9±0.2 10.7±0.4 10.1±0.3 control . Dss ≈ Dss + iPc . Dss + Fs
serum iron (µg/dl) 264.4±22.3 147.9±15.8 189.6±15.3 170.2±18.7 control . Dss + iPc ≈ Dss + Fs . Dss
TiBc (µg/dl) 621.3±52.6 486.0±51.2 644.6±38.0 639.2±45.0 Dss + iPc ≈ Dss + Fs ≈ control . Dss
TsaT (%) 42.5±1.6 30.4±1.8 29.4±1.7 26.6±1.7 control . Dss ≈ Dss + iPc . Dss + Fs
liver enzymes
asT (Ui/l) 96.5±17.1 136.3±18.0 151.8±24.7 162.8±25.0 control , Dss ≈ Dss + iPc ≈ Dss + Fs
alT (Ui/l) 40.2±5.5 61.2±5.5 80.4±7.4 87.3±5.4 control , Dss , Dss + iPc ≈ Dss + Fs
alP (Ui/l) 529.7±22.9 601.8±16.7 648.8±19.3 660.6±25.0 control , Dss , Dss + iPc ≈ Dss + Fs
serum hepcidin (pg/ml) 12.1±0.9 18.6±2.0 22.6±3.9 37.9±4.5 control , Dss + iPc ≈ Dss + Fs , Dss
Notes: Data shown is mean ± standard deviation unless otherwise specified. The order of the groups shown in the last column indicates significant differences with P,0.05 
for , and ., whereas ≈ denotes a nonsignificant difference.
Abbreviations: alP, alkaline phosphatase; alT, alanine aminotransferase; asT, aspartate aminotransferase; Dss, dextran sulfate sodium; Fs, ferrous sulfate; hb, hemoglobin; 
iPc, iron polymaltose complex; TiBc, total iron binding capacity; TsaT, transferrin saturation.
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Figure 1 Gross anatomy, crypt injury, and inflammation of rat colon.
Notes: cumulative scores (mean ± standard deviation) together with representative images of gross anatomy and histology sections. The order of the groups shown below 
the bar charts indicates significant differences with P,0.05 for , and ., whereas ≈ denotes a nonsignificant difference. Arrows indicate points of injury.
Abbreviations: Dss, dextran sulfate sodium; Fs, ferrous sulfate; iPc, iron polymaltose complex.
control . DSS . DSS + IPC . DSS + FS (Figure 3). In 
contrast to the other oxidative stress markers, the catalase 
activity was affected differently by acute colitis and oral 
iron supplementation. Whereas the DSS group showed 
significantly lower catalase activity than the control group, 
oral iron treatment caused a significant increase in catalase 
activity versus the control group. This increase was signifi-
cantly higher for FS than for IPC (Figure 3).
Pathology and immunohistochemistry 
findings in the liver, and liver enzymes
Liver morphology did not reveal any major differences 
between the groups (data not shown). L-ferritin expres-
sion and iron deposits (as Prussian blue staining) were 
significantly higher in the two groups that had received oral 
iron compounds than in the control and DSS groups, with 
no difference between the two iron treatments (significant 
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differences between groups with P,0.05: control ≈ DSS , 
DSS + FS ≈ DSS + IPC) (Figure 2).
The three tested liver enzymes, ALT, AST, and ALP, 
were significantly higher in the groups that received DSS 
versus the control group. For ALP and ALT, the DSS + IPC 
and DSS + FS groups also showed significantly higher values 
than the DSS group (Table 1).
Trends for oxidative stress parameters in the liver 
were similar to those observed in the colon mucosa, and 
oxidative stress increased in the order control , DSS # 
DSS + IPC , DSS + FS (significant differences given in 
Figure 3). As also described for the colon, the catalase 
activity in the liver was affected differently by acute colitis 
and oral iron supplementation, ie, the catalase activity in the 
control group was significantly higher than that in the DSS 
group, and iron supplementation with FS or IPC resulted in 
a significant increase of catalase activity not only versus the 
DSS group but also versus the control group.
Inflammatory markers and hepcidin
All groups with acute colitis presented a significant increase 
in TNF-α and IL-6 expression in the colon and in the liver, 
compared with the control group (Figures 4A and B). This 
increase was significantly exacerbated in the DSS + FS group, 
while the DSS + IPC group was not significantly different 
from the DSS group, resulting in significant differences 
between the groups in the following order: control , DSS ≈ 
DSS + IPC , DSS + FS.
Hepcidin immunostaining and Western blot analysis from 
liver samples (Figures 4A and B) and hepcidin levels in the 
serum (Table 1) behaved similarly, with the same order of 
significantly increasing hepcidin levels between the groups, 
ie, control , DSS ≈ DSS + IPC , DSS + FS.
Spearman nonparametric correlation yielded significant 
correlations between serum hepcidin and the hepcidin expres-
sion in the liver in all groups (data not shown). A positive 
correlation was also found between hepcidin expression in 
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the liver and both inflammatory markers (TNF-α and IL-6, 
colon and liver) in all groups. Although serum and liver hep-
cidin correlated significantly with each other, liver hepcidin 
expression correlated more strongly with the inflammatory 
markers than serum hepcidin.
Discussion
A previous study with healthy, nonanemic rats treated with 
FS or IPC during 4 weeks or 4 months36 demonstrated 
important acute as well as early and late gastrointestinal 
tract and liver toxicity effects induced by FS but not by IPC. 
Among others, FS caused mucosal erosions, increased liver 
enzymes, significantly altered oxidative stress markers, and 
had a more than tenfold lower median lethal dose value 
than did IPC. In another study, the effects of FS, IPC, and 
FF treatments on anemic, pregnant rats were investigated.37 
It was demonstrated that, although all treatments corrected 
anemia, FS and FF, but not IPC, increased oxidative stress 
markers and elicited hepatic damage in pregnant rats and 
fetuses. Moreover, it was shown that IPC, but not FS or FF, 
significantly reduced the levels of the oxidative stress and 
inflammatory markers, which were elevated by the anemic 
status of the animals before treatment.37
The effect of oral iron supplementation in DSS-induced 
colitis models has been investigated previously for FF, 
pentacarbonyl iron, and ethylenediaminetetraacetic acid 
iron(III). It was reported that: 1) FF caused an exacerbation of 
the intestinal inflammation but did not affect the level of 
plasma malondialdehyde, plasma antioxidant vitamins, 
or plasma aminothiols;41 2) pentacarbonyl iron not only 
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worsened the disease activity but also increased oxidative 
stress;40,53 and 3) ethylenediaminetetraacetic acid iron(III) 
increased disease activity, oxidative and nitrosative stress 
in the colon, as well as the risk of colorectal carcinoma in a 
long-term experiment (255 days).54
The present study was carried out to assess the potential 
of FS and IPC to further exacerbate the inflammation and 
oxidative stress induced by colitis in a rat model. DSS-
induced acute colitis in rodents typically induces enhanced 
expression of inflammatory markers including IL-6 and 
TNF-α, reduced food intake, weight loss, and bloody 
diarrhea.38,55 As expected, all these effects were observed 
in the present study. The sharp decrease of Hb, TSAT, and 
serum iron levels after the relatively short period of 8 days 
may be mainly attributed to intestinal blood loss, although 
iron sequestration due to the severe inflammatory response 
may also have contributed to this condition. Because of the 
short treatment time, neither FS nor IPC efficiently corrected 
the Hb level, and they also failed to keep the serum markers 
of iron status, TSAT and serum iron, at an adequate level. 
Yet, serum iron and TSAT were significantly higher in the 
DSS + iron groups versus the DSS group, indicating that 
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iron absorption from IPC and FS took place to some extent 
in spite of the highly inflammatory conditions.
The effects of DSS on the colon were clearly visible in 
the gross anatomy and histology of the colon crypts and have 
been described in earlier studies.38,40,41,53 Treatment with FS 
but not IPC caused substantially more severe lesions and 
more serious inflammation than observed in the untreated 
DSS group (Figure 1). This observation was mirrored in a 
markedly stronger local inflammatory response in the colons 
of the DSS + FS group than in those of the DSS + IPC and 
DSS groups, as indicated by the staining of the inflammatory 
markers TNF-α and IL-6 (Figure 4). Also, hepcidin stain-
ing in the colon was more intense for the DSS + FS group 
than for the DSS + IPC group. The role of colon hepcidin is 
still unclear,56 but these data support a correlation between 
the colon hepcidin levels and the degree of inflammation, 
which was higher with FS than with IPC treatment. Yet, it 
remains to be established whether hepcidin expression rep-
resents a defensive or a pathological response to intestinal 
inflammation.56
The less-intense ferritin staining of the colon villi of 
the animals in the DSS group as compared to those of the 
control group suggests that substantial amounts of ferritin 
were lost into the intestinal lumen as a consequence of the 
damage to the colon mucosa, and/or that iron was exported 
into the blood and not stored in the enterocytes due to the 
severe IDA (Figure 2). In contrast, previous studies in similar 
models showed colon iron deposits by Prussian blue stainings 
in the colitis groups but not in control animals.54,56 Yet, the 
different methodologies to assess tissue iron levels and the 
severity of the disease in our study may well explain these 
discrepancies. The villus tips of the iron-receiving groups, 
however, showed a ferritin staining similar to that of the 
control group. It is likely that the relatively high iron dose 
(5 mg iron/kg of body weight) allowed for iron absorption 
and storage within the enterocytes at the villus tips in spite 
of the damaged colon mucosa.
In the liver, a strong inflammatory response was also 
observed. After DSS treatment, the levels of the markers 
TNF-α and IL-6 as well as hepcidin were strongly enhanced, 
and a further exacerbation was induced by FS but not by IPC 
treatment (Figure 4). Some degree of hepatic damage in all 
the DSS-receiving groups was indicated by the elevated 
liver enzymes, ALT, AST, and ALP (Table 1). We consider 
that the most likely reason for the increase in liver enzymes 
observed with IPC and FS treatment was due to the inflam-
matory status present in the underlying DSS-induced animal 
colitis model; the small increase in liver enzymes induced by 
IPC and FS was not significantly different from that induced 
by DSS only. Consequently, from the liver enzyme results 
in the treated groups, it is not possible to conclude that iron 
treatment by itself exacerbates liver injury. The increased 
liver ferritin and Prussian blue stainings are characteristic 
of iron sequestration under inflammatory conditions, which 
leads to increased iron storage in the liver. In the DSS group, 
the ferritin and Prussian blue liver stainings were normal 
despite the inflammation, an observation that can probably 
be explained by the relatively severe IDA in this group.
As mentioned above, local hepcidin expression in the 
colon may cause local iron sequestration and thus increase 
local ferritin levels, but it does not necessarily correlate with 
increased serum or liver hepcidin levels.56 In our study, how-
ever, the severity of the colitis most likely also triggered the 
systemic response of hepcidin expression in the liver and thus 
led to increased serum hepcidin levels. As expected, the levels 
of serum and liver hepcidin correlated with each other and 
with the levels of inflammatory markers in liver and colon in 
the DSS-receiving groups. The higher serum hepcidin levels 
found in the DSS + FS group versus the untreated DSS group 
could arise from the more-severe inflammation as well as from 
the less-severe IDA present in the DSS + FS group. However, 
the observations that the iron parameters in the DSS + IPC 
group were similar to those in the DSS + FS group, but that 
the levels of hepcidin and inflammatory markers were lower 
after IPC treatment, rather support the interpretation that the 
higher hepcidin levels in the DSS + FS group are a conse-
quence of the more severe inflammatory state. Yet, the role of 
serum hepcidin in the IBD setting is not clear.57–62
Recent studies support the importance of IL-6 signaling in 
the development of IBD; however how this pathway causes 
intestinal inflammation is not fully understood.63 Circulating 
and intestinal levels of IL-6 as well as levels of the soluble 
IL-6 receptor (sIL-6R) are increased in patients with IBD and 
there is growing evidence that increased formation of IL-6/
sIL-6R complexes interacting with membrane-bound gp130 
on T cells via trans-signaling leads to the development and 
perpetuation of IBD.63
The local effects of FS have been ascribed to the formation 
of reactive oxygen species in the inflamed tissue, leading to 
increased inflammatory response and even carcinogenesis,16 
whereas increased serum levels of iron promote the genera-
tion of NTBI, which could provoke oxidative stress in the 
cells of a number of different compartments such as the heart 
and liver.20,22,23,25 In comparison to FS, treatment with IPC in 
addition to DSS caused less (TBARS, GSH:GSSG colon) 
or no (GSH:GSSG liver, CuZn-SOD liver, GPx) additional 
oxidative stress. The physicochemical properties of IPC and its 
mechanism of iron uptake are different from those of ferrous 
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salts, such as FS. IPC is a polynuclear iron(III)-oxyhydroxide 
complex stabilized by a polymaltose shell. This complex is 
stable throughout the whole gastrointestinal tract, a property 
that allows for a controlled release, and thus uptake, of iron. In 
contrast, soluble ferrous salts release large amounts of iron(II) 
ions that can be taken up by paracellular diffusion, which can 
lead to increased levels of NTBI and therefore increased lev-
els of oxidative stress. The different behavior of the catalase 
concentrations in liver and colon, which was lowest in the DSS 
group and only slightly higher in the iron-receiving groups 
than in the control group, could be explained by the severe 
IDA in the DSS group, which may hinder the synthesis of this 
iron-containing enzyme. These observations agree well with 
the effect of FS and IPC treatment in pregnant, anemic rats, 
where FS but not IPC elicited oxidative stress in the pregnant 
rats, fetuses, and placentas.37
Conclusion
Our study shows that, in contrast to FS, IPC treatment during 
DSS-induced colitis in rats does not significantly exacerbate 
colonic tissue erosion, local or systemic oxidative stress, 
or local or systemic inflammation, even at high therapeutic 
doses. This result confirms the favorable properties of IPC, 
which does not release large amounts of ionic iron30,64 in the 
gastrointestinal tract and thus does not provoke local reactions 
in the colon. Moreover, iron from IPC is taken up in a con-
trolled way, a feature which prevents NTBI formation.23,37,64 
Up until now, IPC is the only oral iron supplement that has 
been shown to have no major detrimental effect on disease 
activity, oxidative stress, and inflammatory markers in rodent 
models of colitis and may thus represent a valuable oral treat-
ment for IDA in IBD patients. The favorable properties of 
IPC are especially relevant with regard to the long duration of 
a course of oral iron substitution and the fact that IDA tends 
to be a reemergent condition in IBD patients.35
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